The white skeletal muscle of very long-chain acyl-CoA-dehydrogenase-deficient (VLCAD À/À ) mice undergoes metabolic modification to compensate for defective b-oxidation in a progressive and time-dependent manner by upregulating glucose oxidation. This metabolic regulation seems to be accompanied by morphologic adaptation of muscle fibers toward the glycolytic fiber type II with the concomitant upregulation of mitochondrial fatty acid biosynthesis (mFASII) and lipoic acid biosynthesis. Dietary supplementation of VLCAD À/À mice with different medium-chain triglycerides over 1 year revealed that odd-chain species has no effect on muscle fiber switch, whereas even-chain species inhibit progressive metabolic adaptation. Our study shows that muscle may undergo adaptive mechanisms that are modulated by dietary supplementation. We describe for the first time a concomitant change of mFASII in this muscular adaptation process.
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Keywords: b-oxidation; metabolic regulation; mitochondrial fatty acid biosynthesis Skeletal muscle is characterized by different muscle fiber types defined by specific subsets of genes encoding for contractile and noncontractile proteins which result in phenotypic differences in muscle fibers and muscle groups. Human skeletal muscle commonly consists of more than one fiber type to sustain a wide range of workload and metabolic requirements. Three fiber type isoforms can be identified. The red slow twitch type I fibers contain a large volume of myoglobin and show high mitochondrial density with a preference for fatty acids as substrate for energy production. Type IIa fibers are also described as fast oxidative fibers and are hybrids of type I and type II fibers containing a large number of mitochondria and a high volume of myoglobin. In contrast, the fast twitch type IIb fibers are characterized by a very low mitochondrial content and the energy production mostly relies on glycolysis. These fibers are also known as fast glycolytic fibers. Overall, hormonal factors, endurance training, and weight gain may induce morphological adaptation by inducing specific gene programs [1] [2] [3] [4] . Muscle weakness, pain, and rhabdomyolysis are typical symptoms of the muscular phenotype of very long-chain acyl-CoA dehydrogenase (VLCAD; EC 1.3. 99.3) deficiency (OMIM 201475) . VLCAD deficiency is the most common inherited disorder of the mitochondrial b-oxidation of long-chain fatty acids (LCFAs) with an incidence of 1 : 50 000-1 : 100 000 newborns [5] [6] [7] [8] and affects tissues and organs with a high-energy demand [7, 9, 10] . The main mechanism in the development of symptoms is severe energy deficiency due to a defective fatty acid oxidation with a consequently impaired ketone bodies biosynthesis. Under these conditions, large amount of fatty acids metabolites accumulate in the respective tissues. Fasting and other catabolic stressors as result of illnesses or prolonged exercise may induce or aggravate clinical symptoms. Under these conditions, severe metabolic derangement and death may occur. A long-chain fat-restricted diet and the supplementation of medium-chain fatty acids in form of medium-chain triglycerides (MCT) represent the recommended therapy until today [5, 11] . They may passively cross the mitochondrial membrane avoiding the bottleneck represented by VLCAD deficiency and supply organs and tissues with the required energy. A new therapeutical approach for the treatment of VLCAD deficiency is represented by the application of triheptanoin, a triglyceride with three medium odd-chain heptanoic acids (C7). Triheptanoin has potential anaplerotic effect supplying the citric acid cycle with alternative substrates [12] .
Our own studies in the very long-chain acyl-CoA dehydrogenase-deficient mouse (VLCAD À/À ) showed that despite VLCAD ablation, the tissues develop different strategies to compensate VLCAD deficiency [13, 14] . With special regard to the skeletal muscle, our previous studies showed that intensive physical exercise was associated with a massive accumulation of acylcarnitines in young mice [15, 16] . More recent studies in VLCAD À/À mice at the age of 12 months revealed that the white skeletal muscle had undergone a metabolic switch long-term, which was not especially associated with exercise stress. Importantly, these effects were reversed by the dietary supplementation of MCT [14] .
To address the question whether the metabolic switch in skeletal muscle in VLCAD À/À mice is accompanied by a morphologic transition and whether this process is progressive, we analyzed muscle tissue from wild-type (WT) and VLCAD À/À mice at different ages and compared these data with those obtained from mice fed over 1 year with either MCT or triheptanoin.
We further explored the effects of different dietary fat content on the expression of genes coding for different muscle fiber types and on genes regulating mitochondrial energy homeostasis. These data were supported by proteomic and histological analyses of white muscle and functional assay of glycolytic enzymes.
Materials and methods

Animals
Experiments were performed on intercrosses of C57BL6 + 129sv VLCAD genotypes. Littermates served as controls and genotyping of mice was performed as described previously by Exil et al. [17] . 
Diet composition and supplementation
At 5 weeks of age, mice of each genotype were divided in three groups and fed with different diets for 3, 6, or 12 months. The first group received a normal purified mouse diet containing 5% crude fat in form of LCT, corresponding to 12% of metabolizable energy as calculated with Atwater factors (ssniffÒ EF R/M Control; ssniff Spezialdi€ aten GmbH, Soest, Germany). The treatment recommendation for long-chain fatty acid oxidation diseases includes a strict fat-modified diet in which the normal longchain fatty acids are completely replaced by even mediumchain triglycerides (C8 and C10 chains) [5, 11] . Therefore, the second and the third groups were fed with a diet corresponding as well to 12% of total metabolizable energy. Here, 4.4% from a total of 5% fat was either triheptanoin or MCT (CREMER OLEO GmbH & Co. KG and Basis GmbH, Hamburg, Germany), while the remaining 0.6% was derived from soy bean oil providing the required essential long-chain fatty acids. 
Enzyme activities
Pyruvate kinase (PK) and pyruvate dehydrogenase (PDH) activities were performed in duplicate as previously reported following the manufacturer's protocol [20] . Oxidation rate of palmitoyl-CoA and citrate synthase were performed as described previously [13] .
Histological analysis
The histological assessment of muscle fiber type was performed on tissues from all mice group previously stained with eosin and hematoxylin. The distinction between fast glycolytic type II and slow oxidative type I muscle fibers was done histochemically [21] . With NADH mitochondrial density was measured as previously described [22] . The histological stains were evaluated by a person who was blinded for group status of the animals.
Proteomic analysis
Proteins from tissue of WT and VLCAD À/À mice were extracted by freezing with liquid nitrogen and grinding in a mortar. Resulting powder was re-suspended in 500 lL lysis buffer (100 mM Tris pH = 7.6, 4% SDS including protein inhibitor cocktail; Roche), and samples were boiled during 5 min at 95°C. Pellets resulting after centrifugation at maximum speed were discarded, and protein concentration of the supernatant was determined by Pierce BCA protein assay kit (ThermoFisher Scientific). Five hundred micrograms of protein of each sample was prepared for SDS/ PAGE gel as follows.
Samples were supplemented with Laemmli buffer 6 9 containing 1 mM DTT and boiled for 5 min at 95°C. Subsequently, they were alkylated using 5.5 mM iodoacetamide for 30 min at 25°C. Protein mixtures were separated by SDS/PAGE (4-12% Bis-Tris mini gradient gel), and gel lanes were cut into 10 equal slices. Gel fractions were in-gel digested using trypsin (Promega, Mannheim, Germany) [23] . Digests were performed overnight at 37°C in 0.05 M NH 4 HCO 3 (pH 7.5). About 0.1 lg of protease was used for each gel band. Peptides were extracted from the gel slices with ethanol, and resulting peptide mixtures were processed on STAGE tips as described [24] .
Samples analyzed by MS were measured on LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) coupled either to an Agilent 1200 nanoflow-HPLC (Agilent Technologies GmbH, Waldbronn, Germany). HPLC-column tips (fused silica) with 75-lm inner diameter were self-packed with Reprosil-Pur 120 ODS-3 to a length of 20 cm. No precolumn was used. Peptides were injected at a flow of 500 nLÁmin À1 in 92% buffer A (0.5% acetic acid in HPLC gradient grade water) and 2% buffer B (0.5% acetic acid in 80% acetonitrile, 20% water). Separation was achieved by a linear gradient from 10% to 30% of buffer B at a flow rate of 250 nLÁmin
À1
. The mass spectrometer was operated in the data-dependent mode and switched automatically between MS (max. of 1 9 10 ions) and MS/ MS. Each MS scan was followed by a maximum of five MS/ MS scans in the linear ion trap using normalized collision energy of 35% and a target value of 5000. Parent ions with a charge states of z = 1 and unassigned charge states were excluded from fragmentation. The mass range for MS was m/z = 370 to 2000. The resolution was set to 60 000. MS parameters were as follows: spray voltage 2.3 kV; no sheath and auxiliary gas flow; ion transfer tube temperature 125°C.
Software Xcalibur (Thermo Scientific, Schwerte, Germany) and MaxQuant 1.4.1.2 were used for data acquisition and processing.
RT-PCR analysis
Total RNA from skeletal muscle was isolated with the RNeasy mini kit (Qiagen, Hilden, Germany). Forward and reverse primers were designed with the Primer Design Tool from NCBI (http://www.ncbi.nlm.nih.gov/tools). Gene function and primer sequences are reported in Table 1 . RT-PCR was performed in a single step procedure with the iTaq TM Universal SYBRÒ Green Supermix (BioRad, M€ unchen, Germany) on a CFX96 Touch (BioRad, M€ unchen, Germany). Gene coding for the 18S ribosomal subunit was used as reference.
Statistical analysis
All reported data are presented as mean AE standard error of the mean (SEM). n denotes the number of animals tested. Analysis for the significance of differences was performed using Student's t-tests for paired and unpaired data. To test the effects of the variables, diet and genotype twoway analysis of variance (ANOVA) with the Bonferroni post-test were performed (GraphPad Prism 6.0; GraphPad Software, San Diego, CA, USA). Differences were considered significant if P < 0.05.
Results
The adaptation of muscle fiber type is time dependent and seems to be mediated by mFASII Previous studies suggested that tissues of VLCAD À/À mice differently adapted to VLCAD ablation [13] . In particular, the white skeletal muscle seemed to undergo a metabolic switch toward enhanced glycolysis [13] . In this new experimental setting, we explored the hypothesis that this switch is time dependent and occurs as long-term compensation to sustain a defective b-oxidation.
Measurement of gene expression in mice at different ages showed that at the age of 3 months, troponin genes encoding for oxidative fiber type I were significantly upregulated in VLCAD À/À mice (Fig. 1A) ; however, this process was reversed during aging. Indeed, at the age of 6 months, the expression of the oxidative genes Tnni1, Tnnc1, and Tnnt1 was strongly reduced, and in parallel, we observed an increasing energy deficiency as revealed by the significant upregulation of PGC1a (Fig. 1A) known to regulate the muscle fiber switch [25] . Furthermore, the observed downregulation was particularly evident in 1-year-old mutants, whereas in contrast, they displayed a significantly upregulated expression of genes encoding for glycolytic type II fibers (Fig. 1A) .
Since the oxidation of pyruvate by pyruvate dehydrogenase requires lipoic acid as cofactors which is covalently bound as a prosthetic group of the E2 subunits, we tested whether the expression of genes encoding the mitochondrial fatty acid biosynthesis (mFASII) and the subsequent lipoic acid biosynthesis were also regulated in muscle from mice at the age of 3, 6, and 12 months. As shown in Fig. 1B -C, we observe a progressive upregulation of mFASII and lipoic acid biosynthesis in a time-dependent manner, indicating that the regulation of these mitochondrial pathways occurs in parallel with muscle fiber switch.
Proteomic analysis performed in M. quadriceps muscle from mice at the age of 1 year identified a total of 1702 proteins. Seventy different proteins were downregulated in VLCAD À/À mice and 33 were upregulated. As shown in Table 2 , we observed a marked increase in proteins involved in glycolytic processes such as pyruvate and carbohydrate metabolic pathways, whereas mitochondrial proteins responsible for peptide and carboxylic acid metabolic processes were strongly reduced. To support these findings, we performed immunohistochemical analysis of M. quadriceps from WT and VLCAD À/À mice at the age of 1 year. In accordance to the proteomic data, we observed a marked reduction of muscle fiber type I and a parallel increase of muscle fiber type II in the mutants, as shown in Fig. 2A-F . Because of the strong correlation of these findings and of the high number of the analyzed samples, we focused only on qualitative staining for the evaluation of the muscle fiber changes. Furthermore, western blot analysis performed on quadriceps muscle of mice at the age of 3, 6, and 12 months displayed an initial increase of slow myosin heavy-chain protein typical for oxidative muscle fiber type at 3 months of age, followed by a significant reduction at the age of 6 and 12 months (Fig. 2G-H) .
The long-term supplementation with MCT but not with triheptanoin inhibits the metabolic switch of muscle fiber type from VLCAD À/À mice
To monitor the changes in the oxidative capacity of muscle fibers, we measured the palmitoyl-CoA oxidation rates in mice at 3 and 12 months of age, and we compared the effects of MCT and triheptanoin when supplemented long-term. In line with a previous report [13] , the oxidation rate of palmitoyl-CoA in mice of 3 months of age was significantly reduced as compared with wild-types (WT) under control diet (Fig. 3A ). An even more significant reduction was observed in 1-year-old VLCAD À/À mice (Fig. 3A) . Supplementation with either MCT or triheptanoin diet had no effect on palmitoyl-CoA oxidation rate. Despite the evidence shown by NADH-diaphorase assay suggesting an increase of muscle fiber type II in VLCAD À/À mice at the age of 1 year, no difference between age and diet was also observed in the citrate synthase activity which was used as marker for mitochondrial density (Fig. 3B ) [26, 27] . In contrast, we observed striking differences in the specific activity of PDH and PK. In that, mutants under control diet showed a significant higher PDH and PK activity measured at the age of 1 year as compared to WT under the same dietary regimen ( Fig. 3C-D) . Long-term supplementation of triheptanoin induced a further increase in both enzyme activities as compared with control diet; however, only PK was significantly higher in both genotypes (10.6 AE 1.6 mUÁmg À1 vs 6.4 AE 0.3 mUÁmg À1 for the WT and 10 AE 1.7 mUÁmg À1 vs 7.9 AE 0.3 mUÁmg
À1
for VLCAD À/À mice) (Fig. 3D) . On the other hand, mice supplemented with MCT showed a significantly reduced PDH enzyme activity as compared with VLCAD À/À mice upon a control diet, and also no differences were observed for PK (Fig. 3C-D) . This suggests that in contrast to triheptanoin, MCT does not stimulate glucose oxidation in skeletal muscle. In parallel, we found a significant increase of lipoilation degree in mutants at the age of 1 year upon control diet and triheptanoin supplementation (Fig. 3E-F) . In contrast, MCT diet led to a significant reduction in lipoylation after 1-year supplementation (Fig. 3E-F) . Because of the different responses to the dietary supplementation, we measured the expression of troponine genes in mice supplemented with MCT and triheptanoin at the age of 3 and 12 months. Interestingly, we observed an initial upregulation of oxidative genes in mice supplemented with MCT, whereas triheptanoin induced a downregulation in the mutants (Fig. 4A) .
However, at the age of 1 year, the initial upregulation of the oxidative genes Tnni1, Tnnc1, and Tnnt1 was reversed to normal levels in MCT-treated mice and an effect of partial normalization was also observed in mice supplemented with triheptanoin (Fig. 4B) .
The mFASII and lipoic acid biosynthesis were upregulated at mRNA level in 1-year-old mice (see The experiments were repeated five times with pools generated from protein lysates from five different preparations. LCT: control diet; C7: triheptanoin; C8: MCT; PDH, pyruvate dehydrogenase; aKGDH, alpha-ketoglutarate dehydrogenase. The values are mean AE SEM (n = 10-12). Values denoted by *, #, and § were considered significant if P < 0.05 (two-way ANOVA and Student's t-test). *Significant differences between WT and VLCAD À/À mice under the same dietary regimen. #Significant differences between mice of the same genotype under different dietary regimen. §Significant differences mice of the same genotype at different age.
above); therefore, we tested whether medium-chain fatty acids in form of MCT and triheptanoin may also affect the regulation of these two pathways. As shown in Fig. 4C , mFASII was strongly upregulated in VLCAD À/À mice regardless of the supplemented diet.
Moreover, in WT mice upon MCT, the upregulation of mFASII was particularly evident. In contrast, the upregulation of lipoic acid biosynthesis (Fig. 4D) showed a two-fold increase only in mice treated with triheptanoin as compared with mice under control diet. In contrast, MCT had no effect suggesting that dietary even C8 fatty acids compounds may have a rate-inhibiting-like effect on this pathway.
Discussion
In this work, we reported the metabolic transdifferentiation of the white skeletal muscle from VLCAD À/À mice that occurs in the context of a progressive and time-dependent upregulation of glucose oxidation very likely to compensate for a defective mitochondrial boxidation. We show for the first time that the apparent morphologic transition is associated with changes in two mitochondrial pathways never considered in this process yet, the mitochondrial fatty acid biosynthesis (mFASII) and the lipoic acid biosynthesis. It remains currently unproven how these changes are initiated and whether they are the driving forces for the modulation of skeletal muscle metabolism. Interestingly, long-term supplementation with even medium-chain fatty acids seems to inhibit the progressive metabolic and the very likely morphologic transition of muscle fibers in VLCAD À/À mice. In contrast, mice upon the odd-chain species heptanoic acid showed a stronger upregulation of glucose oxidation than observed in VLCAD À/À mice under control conditions. We, therefore, suppose in line with the observation in untreated mutants that triheptanoin drives the metabolic and likely a morphologic transition of muscle fibers toward glycolytic species. Skeletal muscle is characterized by morphologic plasticity leading to the shift from one fiber type into another. This process is known in athletes since targeted training bouts are able to modify muscle fiber types in order to improve high-performance results [28] [29] [30] [31] . In this regard, conversion between type IIA and type IIX fibers is well described [32] [33] [34] [35] ; however, the shift from muscle fiber type I to type II and vice versa is the result of more complex coordination of different factors including high velocity isokinetic contractions or higher volume endurance type events [36, 37] . Very recently, it has been shown that the use of retroviral zidovudine induced mitochondrial myopathy presenting with mitochondrial DNA depletion, morphological mitochondrial abnormalities, and enhanced glucose oxidation accompanied by the shift from the slow oxidative type I fibers toward the fast glycolytic type II fibers [21] . This indicates that genetic modification induced by dysfunctional energy producing pathways in mitochondria can result in muscle fiber transdifferentiation. This response of the tissue to energy deficiency is also supported by our own results. The skeletal muscle of VLCAD À/À mice likely adapt to energy deficiency by upregulating glucose oxidation and shifting to glycolytic muscle fiber type II over the period of 1 year, as previously suggested [13] . Similar results have also been described in humans. Indeed, mathematical modeling of oxidative ATP metabolism in quadriceps muscle from VLCAD subjects performing 45 min of bicycle exercise also suggests a switch in muscle fiber composition in VLCAD patients from oxidative to glycolytic [38] metabolism but without mentioning the concomitant upregulation of the mFA-SII/lipoic acid biosynthesis pathways. This recent report strongly corroborates our in vivo findings on skeletal muscle from VLCAD À/À mice on this adaptive mechanism due to a defective b-oxidation machinery. Since PDH, one key enzyme of glucose oxidation is dependent on the presence of lipoic acid as cofactor which is synthesized via the mFASII/lipoic acid biosynthesis pathway (Fig. 5) we think that the hypothesized muscle fiber shift and the reported changes in the mFASII/lipoic acid biosynthesis pathways might be linked in some respect. To date, nothing is known about the regulation and involvement of mFASII in energy metabolism. In accordance, our data showed that this effect is age-dependent and inversely correlated to the expression of genes encoding for oxidative muscle fiber types. Previous studies demonstrated that a similar process occurred also in cardiac muscle [39] . VLCAD À/À mice suffered a chronic cardiac energy deficiency which led to the upregulation of the fetal gene program to redirect the energy production toward enhanced glucose metabolism [39] . At molecular level, the maladaptive cardiac energetic profile was regulated by the peroxisome proliferator-activated receptor-gamma coactivator 1a (PGC1a) [40] . However, in skeletal muscle, an upregulation of PGC1a has been described to correlated with a switch from type II to type I fibers [41] by induction of mitochondrial proliferation and activation of mitochondrial oxidative metabolism [42] . However, the increased expression of PGC1a may also paradoxically stimulate glucose metabolism. Indeed, the excessive fatty acid uptake and re-esterification exceeding b-oxidation may exacerbate fat-induced insulin resistance in skeletal muscle [43] . We strongly suppose that in VLCAD À/À mice, the defective b-oxidation may lead to energy deficiency which induces the upregulation of PGC1a. However, this does not lead to mitochondrial proliferation as shown by the unchanged citrate synthase activity but most likely to the accumulation of nonmetabolized fatty acids which are processed to intracellular lipid vesicles. These observations are in line with previous reports on intramuscular lipid accumulation in VLCAD À/À mice [44] and with the data presented here. The regulation of energy homeostasis after the activation of AMP-activated protein kinase [45] through induction of mitochondrial sirtuin 1 [46] via PGC1a is also well known, but again no data are reported about the possible involvement of mFASII. We here show the link between mFASII and defective b-oxidation in the time-dependent muscle fiber switching in VLCAD À/À mice. In particular, mFASII is responsible for the biosynthesis of octanoyl-ACP moieties which are redirected to the biosynthesis of lipoic acid, an essential cofactor for PDH, a-ketoglutarate dehydrogenase (aKGDH), glycine cleavage system (GCSH), and branched-chain keto-acid dehydrogenases (BCKDH) [47] in accordance to our results in white skeletal muscle of 1-year-old mice. Overall, our here presented findings displayed that the upregulation of both pathways occurs in parallel to the changes in muscle fiber type. It has recently been shown that MECR, one protein of the mFASII pathway, regulates gene expression via PPARa and PPARc signaling and modulates the abundance of bioactive lipids [48, 49] . Therefore, a role of this pathway in metabolic regulation cannot be excluded. Although the mFASII pathway was upregulated in all analyzed mice groups independently of the genotype after longterm supplementation with medium-chain fatty acids, we observed a different response of the muscle tissue due to even-(MCT) or odd-chain species (triheptanoin) with regard to the lipoic acid biosynthesis. Indeed, MCT seemed to have an inhibitory effect on fiber switching toward enhanced glucose oxidation as also confirmed by the PDH and PK enzyme activities and by the expression of genes encoding for glycolytic fibers. Since even medium-chain fatty acids are able to cross passively the mitochondrial membranes, they may inhibit the biosynthesis of lipoic acid, despite a slight upregulation at gene level, due to the direct b-oxidation of the C8 fatty acids, thus increasing the mitochondrial ratios of acetyl-CoA/CoA and NADH/NAD + with subsequent inhibition of the pyruvate dehydrogenase activity [50] . Similarly to MCT, triheptanoin undergoes the same metabolic degradation in the first oxidation cycle followed by the synthesis of anaplerotic five-carbon (C5) ketone bodies. However, in mice of both genotypes supplemented with this diet glucose, oxidation was upregulated as well as already reported for the heart [20] . The upregulation of glucose oxidation also in muscle clearly correlates with the upregulation of lipoic acid biosynthesis and subsequent lipoylation degree, as well as with the expression of troponine genes encoding for muscle fiber type II. Recently, it has been reported how triheptanoin improves mitochondrial morphology and content in skeletal muscle of a mouse model of Rett syndrome, an autism disorder associated with impaired mitochondrial dysfunction by supplying the citric acid cycle with anaplerotic intermediates [51] . In contrast to this, no anaplerotic effects have been observed in skeletal muscle of VLCAD À/À mice after supplementation in the long-term (data not shown). These data suggest that even medium-chain fatty acids (MCT) may affect the biosynthesis of lipoic acids via substrate inhibition also altering the ratios of acetyl-CoA/CoA and NADH/ NAD + while triheptanoin had no effect in this regulation.
In light of the recent findings in VLCAD patients [38] , it is conceivable to imagine a similar modulating effect of medium-chain fatty acids also in humans. Since no long-term studies on the effects of mediumchain fatty acids have been performed to date, the impact of the metabolic/ morphologic adaptation on the muscular clinical phenotype is unknown yet. In addition, very recent studies show that despite the slight positive effects of triheptanoin on the cardiac ejection fraction and exercise endurance and tolerance in patients with long-chain fatty acids oxidation defects, the incidence of rhabdomyolysis episodes did not improve [52, 53] .
In conclusion, skeletal muscle fiber types are able to change in VLCAD À/À mice in response to the different energy needs. There is some evidence that these adaptation mechanisms may occur in parallel with the stimulation of mFASII to bypass the defective b-oxidation machinery. Moreover, there is also evidence that morphology and metabolism of muscle fibers in VLCAD À/ À mice may be affected by even and odd mediumchain fatty acids which modulate the transcriptional response in this adaptation process. Although we cannot describe a direct mechanistic involvement, we show for the first time a concomitant change of mFASII and lipoic acid biosynthesis in this muscular phenotypic and metabolic adaptation.
